The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...
A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.
A late-stage trial found a new pill, daraxonrasib, doubled median survival and improved quality of life, compared with ...
Researchers at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) have discovered a previously unknown ...
The eagerly awaited full dataset from the most pivotal pancreatic cancer study in decades didn’t just live up to expectations ...
UVA Health’s Dr. Matthew Reilley said the new drug is extending survival and reinvigorating the search for a cure.
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. This undated microscope image from USC via the NIH ...
Clinical trials at Emory and Piedmont are signaling a potential breakthrough in treating pancreatic cancer, one of the nation’s deadliest diseases.
A new, experimental medication nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a study published Sunday. Researchers say the findings ...
A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how much. Researchers found that oleic acid—the main fat in olive oil and several ...
Data from a major breakthrough in the fight against pancreatic cancer was released this month, highlighting a new pill that targets the root cause of how the disease exists and spreads. Arizona ...
In the study, patients taking the drug lived longer compared to those undergoing chemotherapy. "This study showed that they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results